Details for Patent: 8,871,745
✉ Email this page to a colleague
Which drugs does patent 8,871,745 protect, and when does it expire?
Patent 8,871,745 protects NINLARO and is included in one NDA.
This patent has sixty-one patent family members in thirty-six countries.
Summary for Patent: 8,871,745
| Title: | Proteasome inhibitors |
| Abstract: | The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. |
| Inventor(s): | Olhava; Edward J. (Newton, MA), Danca; Mihaela Diana (Mendham, NJ) |
| Assignee: | Millennium Pharmaceuticals, Inc. (Cambridge, MA) |
| Application Number: | 13/964,708 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; Delivery; |
More… ↓ |
Drugs Protected by US Patent 8,871,745
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | NINLARO | ixazomib citrate | CAPSULE;ORAL | 208462-001 | Nov 20, 2015 | RX | Yes | No | 8,871,745 | ⤷ Subscribe | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY | ⤷ Subscribe | ||||
| Takeda Pharms Usa | NINLARO | ixazomib citrate | CAPSULE;ORAL | 208462-002 | Nov 20, 2015 | RX | Yes | No | 8,871,745 | ⤷ Subscribe | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY | ⤷ Subscribe | ||||
| Takeda Pharms Usa | NINLARO | ixazomib citrate | CAPSULE;ORAL | 208462-003 | Nov 20, 2015 | RX | Yes | Yes | 8,871,745 | ⤷ Subscribe | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,871,745
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2178888 | ⤷ Subscribe | PA2017010 | Lithuania | ⤷ Subscribe |
| European Patent Office | 2178888 | ⤷ Subscribe | 300871 | Netherlands | ⤷ Subscribe |
| European Patent Office | 2178888 | ⤷ Subscribe | 122017000025 | Germany | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
